SCHEMBL17375753

SCHEMBL17375753

C(=Cc1ccccc1)COC(c1ccccc1)C1CO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.44
TDP1 Q9NUW8 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
MAPK1 P28482 2/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AGTR2 P50052 2/20 0.38
SIGMAR1 Q99720 4/20 0.38
HTR2A P28223 3/20 0.38
HTR2B P41595 3/20 0.38
LMNA P02545 2/20 0.38
CYP3A4 P08684 2/20 0.38
HIF1A Q16665 2/20 0.38
OPRM1 P35372 2/20 0.38
GMNN O75496 1/20 0.38
ABCB11 O95342 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17375754 1.00 IDO1 (0.44) IDO1TDP1CYP1A2CYP2D6CYP2C9
SCHEMBL6990568 0.80 MEN1 (0.38) IDO1CYP2D6CYP2C9MAPK1CYP2C19
Chlorobenzene SCHEMBL27657978 0.74 CYP2D6 (0.37) CYP2D6CHRM2CHRM4CHRM5CHRM1
SCHEMBL1170735 0.73 TDP1 (0.49) IDO1TDP1TP53TSHRSMN1; SMN2
SCHEMBL38651360 0.72 IDO1 (0.60) IDO1TSHRCHRM2CHRM4CHRM5
SCHEMBL11295933 0.72 CHRM2 (0.42) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL28184514 0.72 ALDH1A1 (0.39) CYP1A2LMNAALDH1A1
SCHEMBL3687682 0.71 IDO1 (0.44) IDO1TSHRCHRM2CHRM4CHRM5
SCHEMBL151181 0.71 IDO1 (0.44) IDO1TSHRCHRM2CHRM4CHRM5
SCHEMBL15571725 0.71 IDO1 (0.52) IDO1TDP1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170157301-A1 LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS TECHNISCHE UNIVERSITÄET WIEN (AT) 2017-06-08 US disclosed
EP-3160462-A1 LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS Technische Universität Wien (AT) 2017-05-03 EP disclosed
WO-2015196228-A1 LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS TECHNISCHE UNIVERSITÄT WIEN (AT) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157301-A1 LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS CCNH, MYLK, CCAR2 IDO1 3269/4885TDP1 4649/4885CYP1A2 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.